Pfizer To Compromise On NICE Price For Ibrance?
Executive Summary
NICE, the HTA for England and Wales, is poised to say no to Pfizer’s Ibrance (palbociclib), because the cost of the drug is too big in relation to its benefits. The company will likely have to come back with a patient access scheme to secure reimbursement.
You may also be interested in...
Ibrance v Kisqali: Quicker Novartis Discount Helps Cut UK NICE’s Timeline
It took NICE, England’s health technology appraisal body, 84 days to say yes to Novartis’ Kisqali and almost a year to recommend Pfizer’s Ibrance. Willingness to sacrifice on price could have had a big impact on timelines.
Novartis' Kisqali CHMP Nod In Fast-Moving Market
The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer marketing battle that is likely to get more intense.
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.